北京九强生物技术股份有限公司 创业板向不特定对象发行可转换公司债券 2025 年付息公告 | 证券代码: | 300406 | 证券简称: | 九强生物 | 公告编号:2025-050 | | --- | --- | --- | --- | --- | | 债券代码: | 123150 | 债券简称: | 九强转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、"九强转债"（债券代码：123150）将于 2025 年 6 月 30 日按面值支付 第三年利息，每 10 张"九强转债"（面值 1,000.00 元）利息为 10.00 元（含税）。 2、债权登记日：2025 年 6 月 27 日。 3、付息日：2025 年 6 月 30 日。 4、除息日：2025 年 6 月 30 日。 5、"九强转债"票面利率：第一年 0.3%、第二年 0.5%、第三年 1.0%、第 四年 1.5%、第五年 2.3%、第六年 3.0%。 6、"九强转债"本次付息的债权登记日为 2025 年 6 月 27 日，凡在 2025 年 6 月 27 日（含）前买 ...

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-047 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 上述产品为雅培仪器封闭通道配套专用试剂。取得医疗器械注册证丰富 了公司产品类别，有利于增强公司的核心竞争力，对公司未来发展具有正面 影响，但对近期的生产经营和业绩不会产生重大影响，敬请投资者注意风险。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 1 | α-淀粉酶测定试剂 盒（EPS | 底物法） | 京 械 20252400679 | 注 | 准 | Ⅱ | 自批准之日起有效期 至 2030 年 06 月 日 | 18 | 本试剂盒用于体外定量 测定人血清、血浆中 α | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 ...

Group 1 - Banqiao Qiancheng signed a significant contract with Mango Film and Television for a total amount of 372 million yuan, accounting for 50.65% of the company's audited main business income for 2024 [1] - The contract allows Mango Film and Television to use the new media and traditional media broadcasting rights for related film and television works globally, positively impacting Banqiao Qiancheng's financial status and operating performance in 2025 and beyond [1] - Jingwei Huikai plans to sell its wholly-owned subsidiary Changsha Yushun for 112 million yuan, which will no longer be included in the consolidated financial statements after the transaction [1] Group 2 - Minsheng Health's subsidiary received a patent for a strain of lactic acid bacteria that significantly improves sarcopenic obesity, although it has not yet been applied to the company's products [2] - Dafu Technology intends to transfer 27% of its subsidiary Shenzhen Peitian Intelligent Manufacturing Equipment Co., Ltd. for 192 million yuan, maintaining a controlling stake post-transaction [3] - Feilong Co. received orders for high-power electronic water pumps for data centers from a well-known global power electronics provider [4] Group 3 - Yatai Co. was selected as a supplier for a foreign brand's EPB project, with a total sales amount of approximately 680 million yuan over a five-year lifecycle [5] - Gansu Energy's 1 million kilowatt wind-solar integrated project has received approval, representing over 10% of the company's installed capacity by the end of 2024 [6] - Jilin Aodong's subsidiary received approval for a drug supplement application for "Tang Le Capsule," used to treat symptoms related to diabetes [7] Group 4 - Shanshui Technology plans to invest 6 billion yuan in a new chemical materials project, expected to generate an annual output value of 8 billion yuan upon completion [8] - Dazhu CNC's H-share issuance application has been accepted by the China Securities Regulatory Commission [9] - Zhujiang Beer announced the resignation of its chairman due to retirement age, with a new chairman elected on the same day [10] Group 5 - Longkun Technology won a bid for a waste collection service project worth 21.57 million yuan, with a service period of one year [11] - Zhongnan Culture plans to provide financial support of up to 20 million yuan to its subsidiary for daily operational needs [12] - Shangfeng Cement's investment in a company applying for an IPO on the Sci-Tech Innovation Board has been accepted [13] Group 6 - Chuanheng Co. received a patent for a system and method for harmless treatment of phosphorus tailings [14] - Toukeng Life's seven medical device registration applications have been accepted, covering various diagnostic fields [15] - Xingqi Eye Medicine's clinical trial for a new eye gel has commenced with the first subject enrolled [16] Group 7 - Jiebang Technology plans to provide financial support of up to 60 million yuan to its subsidiary for operational needs [17] - Shenzhen Airport reported a passenger throughput of 5.54 million in May, a year-on-year increase of 15.67% [18] - Wan'an Technology received a cash dividend of 30 million yuan from its wholly-owned subsidiary [19] Group 8 - Jiuchuan Bio received a medical device registration certificate for a cystatin C assay kit [20] - Hongqiang Co. obtained a safety production license for its subsidiary, marking the official production of a new project [21] - Xiangtan Electric plans to issue convertible bonds totaling 487 million yuan [22] Group 9 - Guangwei Composite signed a supplementary material procurement contract worth 658 million yuan [23] - Jichuan Pharmaceutical announced a comprehensive tender offer starting June 18, with a price of 26.93 yuan per share [24] - Aerospace Rainbow plans to distribute cash dividends of 0.60 yuan per share [25] Group 10 - Industrial Bank plans to distribute cash dividends of 1.06 yuan per share, totaling 22.433 billion yuan [26] - China Automotive Research will repurchase and cancel 230,800 restricted shares due to the retirement of original incentive objects [27] - Annie Co. announced abnormal stock trading fluctuations but confirmed no significant changes in its operations [28] Group 11 - Giant Network confirmed no undisclosed significant matters following abnormal stock trading fluctuations [29]

金十数据6月16日讯，九强生物6月16日公告，公司胱抑素C测定试剂盒（胶乳免疫比浊法）获得北京市 药品监督管理局颁发的医疗器械注册证。本试剂盒用于体外定量测定人血清、血浆或尿液中的胱抑素C （Cys-C）含量。 九强生物：公司新产品获得注册证书 ...

关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | | 产品名称 | | 注册证编号 | | | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 胱抑素 | C | 测定试剂 | 京 械 | 注 | 准 | | 自批准之日起有效期 | 本试剂盒用于体外定量 测定人血清、血浆或尿 | | 1 | 盒 法) | (胶乳免疫比浊 | | 20252400669 | | | Ⅱ | 至 2030 年 06 月 08 日 | 液中的胱抑素 C（Cys-C） 含量。 | 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公 司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩不会产生重大影响，敬请投资者注意风险。 | 证券代码：300406 | 证券简称 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-045 债券代码：123150 债券简称：九强转债 持股 5%以上的自然人股东 ZHOU XIAOYAN 女士保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 北京九强生物技术股份有限公司(以下简称"公司"或"九强生物")于 2025年2月17日披露了《关于持股5%以上股东减持股份计划预披露公告》（公 告编号：2025-006）持有公司股份30,969,636股（占公司当时有表决权股份 比例的5.30%，"公司当时有表决权股份"为截至2025年2月14日总股本剔除 公司回购专用账户中的股份数量，下同）的自然人股东ZHOU XIAOYAN女士计 划自上述预披露公告披露之日起十五个交易日后的三个月内（即2025年3月 11日至2025年6月10日）以集中竞价和/或大宗交易方式减持本公司股份，计 划减持数量不超过619,393股（占公司当时有表决权股份比例的0.11%）。其中， 通过集中竞价方式减持的，任意连续90个自然日内减持股份总数不超过公司 有表 ...

Core Viewpoint - The company Jiukang Bio has a current stock price of 13.88 yuan, with a rolling PE ratio of 16.49, which is the lowest in the past 15 days, and a total market capitalization of 8.166 billion yuan [1]. Company Summary - Jiukang Bio specializes in the research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1]. - The main products include in vitro diagnostic reagents, in vitro testing instruments, instrument leasing, inspection services, laboratory assistance, and other businesses [1]. - The company was recognized as a "National Enterprise Technology Center" on February 22, 2023, as part of the 29th batch of newly recognized national enterprise technology centers [1]. Financial Performance - For the first quarter of 2025, Jiukang Bio reported an operating income of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1]. Industry Comparison - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, placing Jiukang Bio at the 39th position within the industry [1][2]. - The company has a total of 8 institutional holders, including 7 funds, with a total holding of 131.7025 million shares valued at 2.06 billion yuan [1].

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-044 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公 司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩不会产生重大影响，敬请投资者注意风险。 特此公告。 北京九强生物技术股份有限公司 董事会 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | | 注册证编号 | | 注册 类别 | | | | 注册证有效期 | | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 二氧化碳质控品 | | 京 械 注 202 ...

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Jiukang Biological Technology Co., Ltd., indicating a significant decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1] - Jiukang Biological's stock closed at 13.57 yuan, with a rolling price-to-earnings (PE) ratio of 16.12 times, and a total market capitalization of 7.984 billion yuan [1] - The company ranks 40th in the medical device industry, which has an average PE ratio of 49.51 times and a median of 36.17 times [1][2] Group 2 - As of the first quarter of 2025, eight institutions hold shares in Jiukang Biological, with a total of 131.7025 million shares valued at 2.06 billion yuan [1] - The company's main business includes research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1] - Jiukang Biological was recognized as a "National Enterprise Technology Center" in February 2023, reflecting its commitment to technological advancement [1] Group 3 - The latest financial results show that Jiukang Biological achieved an operating income of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1]